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1. Introduction
Skin melanoma is a devastating disease, frequently diagnosed in human and dogs, accounting
for 0,8% - 2% of all skin tumors in latter species [1].
Melanocytic tumours are common neoplasms in dogs, accounting for 4 to 7% of neoplastic
lesions in general, and up to 7% of all malignant tumours [2,3]. They generally arise on the oral
cavity (Figure 1), lip, skin (Figure 2) and digit, amongst other locations (Figure 3) [4].
Figure 1. Canine oral melanoma (courtesy of Dr. Abel Fernandes).
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Figure 2. Canine cutaneous melanoma.
Figure 3. Canine ocular melanoma.
Biologic behaviour of these tumours is often related to its location. Over 85% of melanocytic
lesions located on haired skin are described as of benign behaviour. The majority of oral and
mucocutaneous junction melanomas, with the exception of the eyelid, and 50% of digital
melanomas originated from the nail bed are reported as malignant [5,6].
Cutaneous canine melanocytic lesions are usually benign [7,8]. They are generally detected at
a late stage, when excision is rarely curative and metastasis is often detectable in regional
lymph nodes [7]. Malignant tumors are found most frequently on the head, ventral abdomen,
and scrotum [7]; in the last one, they represent 3,1% of all cutaneous malignant melanomas
and 4,7% of scrotal tumours [9]. Amelanotic lesions can occur as cutaneous neoplasms, but are
more frequent in the oral cavity, and tend to be behaviorally malignant [10].
Metastasis are often found on regional lymph nodes and lungs, but organs as brain, heart and
spleen are also commonly affected [11].
Veterinary nomenclature of canine melanocytic tumours has been subjected to many contro‐
versies and changes over time. Through this article, in accordance with the revised World
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Health Organization classification system, and in order to simplify and avoid confusion, the
authors describe benign lesions as melanocytoma, whereas malignant lesions are referred to
as melanoma [12].
Etiology of this neoplasms is still uncertain, and several factors may be related, such as
consanguinity, trauma, chemical exposure, hormones and genetic susceptibility [10]. Unlike
humans, ionizing solar radiation exposure doesn’t seem to be related to canine melanoma
initiation [4].
Canine melanocytic tumour diagnosis often represents a challenge for the pathologist, since a
high number of neoplastic lesions are quite similar in terms of its clinical and histologic
appearance, including carcinoma, sarcoma, lymphoma and plasmocitoma, amongst others
[10]. Indeed, cutaneous neoplasms with malignant behavior are more difficult to distinguish
histologically from benign neoplasms than oral or lip neoplasms [13].
Diagnosis is usually based on fine-needle aspiration citology, but biopsy for histopathological
examination is essential to determine its malignant potential [4,14]. The most reliable histologic
criteria is the mitotic index, defined as the total number of mitotic figures observed per ten
high-power light microscopic fields, which is known to be 90% accurate [5,6,15].
Immunochemistry has arised as an extremely useful tool, for both diagnostic and prognostic
purposes. A positive diagnostic for melanocytic neoplasms is obtained with a positive labelling
of S100 protein, vimentine, Neuron Specific Enolase (NSE) and a simoultaneous negative
labelling with cytokeratine [16].
The treatment of choice for local cutaneous melanomas is surgical excision; tumours with
benign histopathology criteria have an excellent prognostic after this surgery. However, for
malignant tumors, the prognostic is guarded, since metastatic rates of 30-75% have been
reported [5,6].
Alternative therapy methods described in the literature include systemic chemotherapy,
radiotherapy [17], photodynamic therapy [18], local hyperthermia [19,20] and intralesional
injection of cisplatin or carboplatin.
The  poor  responses  to  the  conventional  therapy  are  leading  to  a  development  of  new
immunotherapy procedures – including intralesional adenoviral vector-mediated transfer
of  CD40L,  a  tumor  necrosis  factor  gene  [21],  therapy  with  a  plasmid  DNA  encoding
staphylococcal  enterotoxin  B  [22],  and  systemic  tratment  with  liposome-encapsulated
muramyl tripeptide [23].
At last, the most promising therapy appears to be a xenogenetic human tyrosinase DNA
vaccine, with minimal local reaction and no systemic toxicity signs, and a great clinical
responde with significant increasing of the survival time [24].
In this paper, the authors aim to contribute to the understanding of melanocytic tumours in
the dog, making a critical review of the literature and discussing the parameters currently
considered valid for diagnosis use in canine melanocytic neoplams.




Cutaneous melanocytic tumours are most common in older dogs (mean age of 9 years old) [25],
with a higher mean age for dogs with malignant melanocytic tumours (12 years). However,
age has not been related with the patient clinical outcome and survival time [26].
Although all breeds of dog (and crossbred animals) may be affected, some breeds are reported
as predisposed, including Schnauzer, Doberman, Scottish Terrier, Irish Setter, Golden
Retriever, Chow Chow, Cocker Spaniel, German Shepherd and Rottweiler [4,27]. Breed
predisposition is thought to be related to an underlying genetic risk and/or increased pigmen‐
tation in the described above breeds [4].
One study [6] has also established a relationship between patient breed and tumour behavior,
likely due to genetic susceptibility, as prior described. In the referred work, melanocytic lesions
tended to be behaviorally benign in Doberman pinschers and miniature schnauzers, while
miniature poodles were the mostly affected breed with malignant melanoma. However, it
must be noted that oral neoplasms were also included in that study.
An early report described a higher frequency of these lesions in male dogs [28], but recent
literature denies gender predisposition [6,27,29-31].
3. Pathogenesis
Melanin is a dark-brown pigment synthetized by melanocytes, dendritic cells found within
the basal layer of the epidermis. These cells are dispersed from each other, located between
basal keratinocytes, forming adherent and regulatory junctions mediated by epithelial
cadherin (E-cadherin) molecules. After its synthesis, melanin is retained in melanosomas and
transferred to the adjacent keratinocytes [32].
Conversion of normal melanocytes to clusters of neoplastic melanocytes is a process composed
by a series of events: initiation, promotion, transformation and metastasis [4].
Little is known about initiation on most animal melanomas, but ionizing solar radiation
exposure – the main initiator factor in Human melanomas [33] - doesn’t seem to be related to
canine melanomas [4]. A higher incidence of spontaneously mutated cells due to familiar
clustering through inbreeding may be a critical initiation factor in domestic animals.
Malignant transformation of canine cutaneous melanocytomas is very uncommon. Regard‐
ing  cutaneous  melanomas,  there  are  a  few  published  case  reports,  including  one  by
Valentine and team [34], which have described a single case of malignant transformation
of a congenital melanocytic nevus is a Golden retriever. Conroy [35] described two cases
of  melanoma  originated  from  junctional  or  dermal  hamartomas  and  a  single  case  of  a
primary melanomas originated from a subcutaneous melanocytoma have also been reported
[36]. In summary, canine cutaneous melanomas are thought to arise de novo from epider‐
mal and dermal melanocytes.
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Promotion phase is related to mutated cells proliferation, with subsequent amplification of cell
population and origin of additional mutations [4]. Melanoma promoters include chronic
trauma, chemical exposure, drugs and hormones [10], and its action results in reactive
hyperplasia of the epithelium, with disruption of regular keratinocyte-melanocyte interactions
and proliferation of initiated cells.
The next step in carcinogenesis involves a series of transformation events. Recent develop‐
ments in genetic and molecular study techniques have identified the role of a few tumour
suppressors in melanoma cell lines, giving new insights on the importance of these molecules
in canine melanoma development. A reduction or loss of p16 expression was one of the most
commonly found changes, in both benign and malignant tumours, suggesting that inactivation
of this pathway is a critical step in the pathogenesis of melanoma [37]. Altered expression of
PTEN, TP53, Rb and p21 have also been related to its progression [38], as well as the presence
of various oncogenes (as a result of proto-oncogenes mutation), such as c-myc, c-erb-B-2, c-
yes, c-kit and ras [4].
After local proliferation phase, neoplastic cells may acquire a malignant behavior, and
disseminate through hematic or lymphatic vessels to various other organs, originating
secondary neoplasms known as metastasis. This complex process has it start with loss of
adhesion and detachment of neoplastic cells from the primary mass, hematic and lymphatic
vessels intravasion and attachment and proliferation within a secondary location [4].
Metastasis process is dependent of various adhesion molecules regulation by neoplastic cells.
Several studies have shown an association between decreased and altered expression of E-
cadherin, a calcium-dependent adhesion molecule responsible for melanocyte-keratinocyte
interaction, and canine cutaneous melanoma progression [39,40]. CD44, a second transmem‐
brane glycoprotein which facilitates metastasis, is required for several processes, including
hyaluronate degradation, cell aggregation and migration, angiogenesis and hematopoiesis [4].
Down-regulation of regular CD44 plus up-regulation of CD44v5 has also been associated with
melanoma metastasis, particularly with lymph node metastasis [41].
Autonomous growth is a key requirement for both primary and secondary neoplastic devel‐
opment. The most important autocrine growth factors in animal melanoma include basic
fibroblast growth factor (bFGF), melanoma growth stimulatory activity or growth regulated
proteins, platelet-derive growth factor-A, α-melanocyte stimulating hormone, and a series of
interleukins (IL-8, IL-10 and IL-18) [4].
4. Gross morphologic features
Macroscopically, canine malignant melanoma cannot be differentiated from melanocytoma
[42]. Melanomas in dogs tend to be dermal in location, unlike Human melanomas – which are
intraepidermal with some degree of dermal invasion. Prognostic schemes, such as Clark’s level
or Breslow thickness, built nased on depht of dermal invasion, are not applicable on canine
lesions [43].
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Canine melanocytomas share some aspects with Human benign melanocytic lesions, in terms
of clinical evolution most common metastatic locations [42], and genetic alterations [44].
Cutaneous melanocytomas are usually symmetrical, circumscribed, but encapsulated [43],
solitary, black, brown, or gray cutaneous alopecic nodules [43,45] with a variable size with
range of 1-4 cm in diameter (Figure 4 and Figure 5) [43]. Epidermis is usually intact, and
alopecia is frequent. Epidermal cells may be hyperpigmented, and the majority of dermal cells
are replaced by the tumoral ones, which in larger masses might also extends into the subcu‐
taneous tissue. The tumors may have a varieated appearance, with areas of pigmentation
intermingled with no pigmented regions [42].
Canine cutaneous malignant melanomas can vary considerably in appearance, regardless of
the location. Melanomas tend to be asymmetrical. The asymmetry may be most readily
recognizable in the epidermal component of junctional tumors [43]. Melanomas size vary from
some milimiteres to as large as 10 centimeters in diameter (mean range being 1 to 3 cm in
diameter) [43], but this is not a reliable indicator of malignancy [13,42]. The color is variable,
ranging from gray or brown to black, red, or even dark blue [7]. Cutaneous melanoma
presentation includes smooth domes, sessile nodules, polypoid, plaquelike [7,43], or even
lobulated masses [7]. The larger ones are often ulcerated [7,43]. The tumors may invade deeply
into the subcutaneous tissue and along fascial planes [42].
Figure 4. Canine cutaneous melanoma.
Figure 5. Canine cutaneous melanoma.
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5. Cytological diagnosis
Microscopic examination of a cytological specimen obtained through fine needle aspiration
has become a valuable technique to obtain a preliminary, and often definitive, diagnosis [46].
Being a quick, non-evasive and inexpensive procedure, it can also provide information on the
stage, prognosis and metastasis evidence. Its main limitation reside on the fact that non-
pigmented melanomas may strongly resemble other neoplastic lesions, and the amount of
cytological sample might be very small and not fully representative of the lesion [4,46].
Several studies in Human cancer have described a strong accuracy in cytological examination
in comparison with histopathological findings [47,48], but there are only few studies on the
subject in Veterinary Medicine [49]. For instance, Ghisleni and others [50] evaluated a series
of cutaneous and subcutaneous masses from dogs and cats through histopathology and
cytology, describing an agreement between both techniques in 90.9% of the samples.
Melanocytic tumours are characterized by the presence of cells with abundant cytoplasmatic
melanin granules. Neoplastic cells may appear with an epithelial (cohesive cells), mesenchy‐
mal (single oval or spindle-shaped cells) or round cell morphology. Nuclei may present a
central or eccentric location, and is often solitary, though multinucleated forms are occasionally
found. Nucleoli tends to be very prominent, with variable shapes such as round, oval or
angular. These cells have a light basophilic cytoplasm, with a moderate to high nuclear-
cytoplasmatic ratio. Varying degrees of pigmentation might be found within the same tumour
smear [4,46], (Figure 6 and Figure 7).
Malignant criteria consist, most importantly, of marked anisokaryosis and nuclear pleomor‐
phism, but also of the presence of large and atypical nucleoli [46]. Mitotic index, the most
reliable criteria in histopathological evaluation, has no use in cytology. Regional lymph nodes
are the most commonly evaluated site while monitoring for metastasis [4].
Figure 6. Canine cutaneous melanoma (Wright, 100x).
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Figure 7. Canine cutaneous melanoma (Wright, 400x).
6. Histological diagnosis
Histological characteristics of canine melanocytic neoplasms were defined by World Health
Organization, in International Histological Classification of Tumours of Domestic Animals, back in
1974 (Figure 8 and Figure 9) [13].
Figure 8. Canine cutaneous melanocytoma (H&E, 200x).
Histological appearance does not always correlate well with biological behavior [8]. More
recent studies have provided a numerical ‘‘tumor score’’ taking into consideration mitotic
index, nuclear atypia, inflammation, necrosis and volume which appears to have improved
correlation between histology and behavior [8].
The term nevus, commonly used in describing pigmented melanocytic lesions of the epidermis
and dermis in humans, is not used in veterinary dermatopathology [7].
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In this chapter we review several histological parameters on their ability to diagnose and
predict prognosis (i.e., prediction of mortality) of canine melanocytic neoplasms. Malignancy
celular features include a characteristic large nucleous, nuclear atypia, hyperchromasia,
abnormal chromatin clumping and anomalous mitotic figures [51].
6.1. Predominant cell type
Melanocytic neoplasms are generally composed of one of the following cell types: epithelioid
(Figure 10), spindle, mixed (Figure 11), dendritic [51,52], and round cells [43]. Other less
commonly described cell types include signet ring and ballon cells [51]. All these cell types
may occur either alone or in combination [43]. In melanomas, ganglion cell and multinucleated
giant cell forms also may be observed [43]. The epithelioid cell type is the most common type
in all locations, whereas a mixture of cell types is seen with less frequency [51].
The epithelioid cells are round, with discrete cell borders, abundant glassy cytoplasm,
appearing arranged in sheets and larger nests [43]. Similar to their spindle-shaped counterparts
melanomas may exhibit large ovoid nuclei and prominent nucleoli [7,43], marked anisokar‐
yosis and variable chromatin patterns [43].
The spindle cell tumors are arranged in streams and interweaving bundles, resembling
fibrosarcoma or neurofibrosarcoma presentation. In malignant lesions, the nuclei are large and
fusiform with prominent nucleoli [7,43], and moderate to marked nuclear pleomorphism is
seen [43]. Spindle cell predominant morphology was statistically associated with benignity in
one study (in 71% melanocytomas in contrast to 29% melanomas) [43]. The mixed type consists
of both cell morphologies and patterns [7].
Dendritic melanocytes have a highly angular shape, sometimes with long cytoplasmic
processes, and are usually arranged in small nests [43] or organized in tightly swirling streams,
often with a fingerprint pattern [7]. The dendritic or whorled forms occurs only in the skin [53].
Figure 9. Canine cutaneous melanoma (H&E, 200x).
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Round cells tumors have round to polygonal cells arranged in sheets as dense packets of cells,
the packets being separated by a scant stroma. The nuclei is large and round in melanomas [43].
The signet-ring cell tumors consist of compact neoplastic clusters, with round to ovoid cells
presenting a faintly-eosinophilic cytoplasm and an intensely-stained periphery. A vesicu‐
lar  nuclei,  crescent-shaped,  and  with  a  peripheral  location,  gives  the  cell  a  signet-ring
appearance [52].
Figure 10. Epithelioid cell canine cutaneous melanoma (H&E, 400x).
Figure 11. Mixed cell canine cutaneous melanoma (H&E, 400x).
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Balloon cells are found organized in groups, separated by collagenous septa [52]. The cells are
round to polyhedral and have clear or faintly eosinophilic cytoplasm [43,52]. In melanomas,
the nuclei are round situated mainly at the periphery of the tumor cells [52]. Usually contains
one central prominent nucleolus [7], which sometimes is difficult to detect. Heterochromatin,
which is sparse, is dispersed throughout the nuclei [52].
Benign melanocytic cells present an enlarged vesicular nuclei with small nucleoli. Nuclear
shape vary on according to the predominant tumour cell type. Mitotic figures are rare, and
mitotic atypia is rarely observed. [43].
Although cell type appears to play some role in the prognosis of ocular melanocytic neoplasms,
this feature lacked significance in prognosis of melanocytic tumors occurring in the mouth,
feet, buccal mucosa and skin of dogs in several studies [8]. On the contrary, the epithelioid
shape was associated with an unfavorable course, for 8/15 cases. The difference seems to be
significant (p = 0,03) [12].
6.2. Nuclear atypia
One of the major criteria of malignancy in melanocytic neoplasms arising at any pigmented
anatomic site is nuclear atypia. This feature is more valuable in epithelioid tumours than in
spindle, whorled type or signet-ring cells, due to the insufficient nuclear detail associated with
the later neoplasms [8,44,54]. However, not all studies are consensual [12].
Well-differentiated tumoral melanocytes have a small nucleus with one central nucleolus [8].
In contrary, undifferentiated tumours generally present cells with multiple, large, irregular
and eccentrically nucleoli [8].
Several criteria are used to estimate nuclear atypia, including the percentage of nuclei involved
[8]. Figures 12 and 13 (below) present moderate and severe nuclear atypia, respectively.
6.3. Mitotic index
In animal cutaneous and eye melanocytic neoplasms, mitotic index (MI) is the most reliable
histological feature for distinguishing malignant from benign tumors [44,51], and also in
predicting the clinical course of the disease [8]. In cutaneous melanoma, an MI of ≥3/10 hpf is
significantly correlated with decreased survival [55].
The number of mitoses is usually lower in melanocytomas [<3 mitotic figures per 10 high power
fields (hpf)] than melanomas [42,44,53].
In one study, the mitotic index was strongly correlated with the clinical outcome of tumors.
For tumors with a favorable outcome, the mean value of the number of mitosis (on 10 randomly
selected high power fields) was 1,98 (from 0 to 27). For tumors with a malignant behavior, it
was 18,53 (from 0 to 75) [12].
The evaluation of the MI in conjunction with nuclear atypia classification (Figure 13) offers a
more precise value the histological diagnosis [8].
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Figure 12. Canine cutaneous melanoma with moderate diferenciation (H&E, 400x).
Figure 13. Canine cutaneous melanoma with evident nuclear atypia and numerous mitosis (arrow), (H&E, 400x).
6.4. Cellular pleomorphism
Cellular pleomorphism criteria include several features, such as cell size and shape, pigmen‐
tation degree and nuclear features (including prominence of nucleoli and chromatin pattern).
The usefulness of these parameters as individual prognostic factors is doubtful; however, it
increases when these are used together [8,27].
6.5. Degree of pigmentation
Degree of pigmentation is highly variable, even within a single smear (Figures 14, 15 and 16).
Even on histological evaluation of amelanotic-classified tumours is common to detect a few
very fine pigment granules in some cells. These are generally punctuate, spherical or elongated,
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as observed in pigmented keratinocytes. Cells with a very fine pigment may present a dusty
gray appearance, instead of the typical granulation image [7]. In summary, it can be difficult
to accurately diagnose an amelanotic melanocytic neoplasm and to define the degree of
pigmentation [13].
Individual tumoral cells possess a different amount of melanin, which granules are generally
small and uniform in size within the same cell. Splindle, round to polygonal, and balloon cells
have sparsely-distributed melanin granules, while large epithelioid and dendritic cells are
known to have a higher degree of pigmentation [43].
The majority of canine melanocytomas (except for ballon cell ones) have marked to moderate
melanin pigmentation overall, especially in the superficial aspect of the tumors [43]. Similarly
to cellular morphology, the degree of pigmentation of neoplastic cells was not an indicator of
prognosis [12].
Figure 14. Canine cutaneous melanoma with marked pigmentation (H&E, 400x).
Figure 15. Canine cutaneous melanoma with moderate pigmentation (H&E, 400x).
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Figure 16. Amelanotic melanoma (H&E, 400x).
6.6. Junctional activity
Junctional activity refers to the proliferation of neoplastic melanocytes at the interface between
the epidermis and dermis or epithelium and submucosa [53].
The presence or absence of junctional activity is not specific to melanoma and often occurs in
melanocytomas [7], however, malignant melanomas arising in the skin often show marked
junctional activity, (Figure 17 and Figure 18) [42].
Junctional activity was not statistically associated with survival for skin neoplasms in one
study [8]. In contrast, another work considered junctional activity as an independent prog‐
nostic factor (p =0,0239) for cutaneous melanocytic neoplasms, and found that its occurrence
was associated with a longer survival time (p = 0,0046) [55].
Figure 17. Canine cutaneous melanoma without junctional activity (H&E, 200x).
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Figure 18. Canine cutaneous melanoma with junctional activity (H&E, 400x).
6.7. Intraepithelial neoplastic cells
The  presence  of  intraepidermal  tumoural  cells  can  be  graded  as  absent,  slight  (25%  of
neoplastic melanocytes in epidermis), moderate or prominent (more than 50% of tumour
cells are present in the epidermis) [44]. However, this feature appears not to be of prognos‐
tic significance [8].
In a recent study was found that the samples of canine melanomas presented medium to
prominent scatter of intraepidermal melanocytes, lower pigmentation, and higher nesting of
intraepidermal melanocytes, in comparison with melanocytomas [44].
In most melanocytomas, the overlying epidermis is hyperpigmented, regardless of the
presence or absence of intraepidermal clusters of neoplastic melanocytes [43].
6.8. Ulceration
Canine melanomas are most frequently ulcerated [44] and particularly larger masses [43] than
melanocytomas.
According to Laprie and team [55], ulceration might be taken as a prognostic marker for this
neoplasms. In the referred work, the presence of an ulcerated epidermis was associated with
a shorter survival time (p = 0,0023) and shown to be an independent prognostic factor (p =
0,0065) [55]. However, two other studies found no correlation between ulceration and clinical
evolution of lip, nail bed [27] or cutaneous melanocytic neoplasms [12,27].
6.9. Level of infiltration/invasion
Melanocytic tumours strictly limited to the dermis, with a shallow depth, are associated with
a greater survival time (p < 0,0001), and deep level of infiltration has been shown to be a
significant prognostic factor (p = 0,0012) [55]. One other study that evaluated the level of
invasion (in cutaneous and subcutaneous tissues) concluded that tumors confined to the
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superficial dermis were associated with a benign course in 94% of cases. On the other hand,
tumors reaching the deep dermis and the subcutis showed a malignant behavior; however,
the sample number were too low to allow for a conclusion [12].
6.10. Necrosis
Necrosis is a common feature, particularly in larger masses [43]. The presence of necrosis was
correlated with malignancy and with a short survival time in a study set of 389 melanocytic
neoplasms containing both benign and malignant lesions from various locations (mouth, feet
and lip, skin) [8]. In other report with a set of 38 malignant melanomas from various locations,
no correlation was found with survival time [54]. In summary, necrosis is considered of limited
prognostic value in animals [7].
6.11. Morphologic classification
Melanocytomas include dermal, compound, and balloon cell tumors, as well as multiple
dysplastic melanocytoma syndrome in dogs [43].
Dermal melanocytoma are strictly intradermal in location and larger tumours may extend into
the subcutis [43]. Melanocytomas are generally composed by spindle cells disposed in bundles,
nests and whorles, with a moderate cellular concentration and a lack of stromal collagen
[43,45]. Melanophages might be dispersed throughout the tumoral nodule or in aggregates
[43]. Mitotic figures are ocasionally seen (inferior to 1 per 10 high power fields), and mitotic
atypia is not observed [43].
Some dermal melanocytomas are composed of epithelioid or dendritic cells that are heavily
pigmented [43]. Nuclear morphology may be obscured by the large amount of pigment [43].
Although nuclei may be large, there is minimal nuclear pleomorphism [43].
A compound melanocytoma has a wedge-shaped configuration, and its description refers to
the fact of including both junctional and dermal components. A numerous and densely packed
tumor cell population is present in the dermis, while a variable amount of tumor cells accu‐
mulate in clusters and nests within the epidermis, along the dermal–epidermal junction and
in the outer follicular wall – this pattern is referred to as ‘junctional activity’ [43].g
Balloon cell melanocytoma have a dermal location, and are predominantly composed of large
round cells [43,45], although some fusiform or polygonal melanocytes might be present [42],
with an abundant, pale eosinophilic and finely granular cytoplasm [42,43,45]. These lesions
often lack readily visible pigmentation; however, dust-like melanin granules may be detected
in small numbers [42,43]. Nuclei are small, uniform, and ovoid [43,45] and mitotic figures are
rarely observed [42,43].
Multiple dysplastic melanocytoma syndrome mostly resemble compound melanocytomas on
low magnification. However, their incidence increases in larger lesions. Also, cytologic atypia
and mitotic figures are present and some of the proliferating melanocytes have irregularly
shaped and enlarged hyperchromatic nuclei [43].
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Canine melanocytoma–acanthomas are mixed tumors that are composed of a benign melano‐
cytic proliferation, resembling compound melanocytoma, and a benign epithelial proliferation
[43,45]. The epithelial component usually appears follicular and resembles an isthmus-type
tricholemmoma or infundibular keratinizing acanthoma [43]. The epithelial population forms
a mass in the dermis composed of cords and nests with occasional small cystic structures
containing keratin [45]. Melanocytic cells form nests in the epidermis and sometimes in the
cords of epithelial cells within the dermal mass; melanocytic spindle cells can form whorls and
bundles between the epithelial cords and nests [45]. A dermal melanocytoma– acanthoma has
been immunophenotyped in a German Shepherd dog identifying the presence of keratinocytes
and melanocytes [56].
Dermal melanomas have no junctional activity, but in some cases the tumour might extend
deeply into the subcutaneous tissue. There might be a predominance of a certain cell type, but
most tumors reveal a mixture of spindle cells, round to polygonal cells, and/or epithelioid cells.
While spindle cells are poorly pigmented, more round and epithelioid cells tend to have a
moderate to abundant amont of melanin granule [43]. Other important features in this kind of
neoplastic lesions include a marked nuclear pleomorphism, nucleolar prominence, a moderate
mitotic rate (3 or greater per 10 high power fields), atypical mitotic figures, asymmetry of the
tumor nodule and a lymphoplasmacytic cell population [43].
Melanomas have an obvious ‘junctional activity’ pattern, with tumor cells distributed through
the dermal–epidermal junction, as well as at higher levels of the epidermis, particularly in
those of the nail bed and lip [43]. The intraepidermal element is mainly composed of epithelioid
melanocytes, disposed individually or arranged in nests and clusters [43]. Tumours with
numerous melanocytes distributed through all levels of the epidermis are referred to as lesions
with a ‘pagetoid’ pattern [43]. Other melanomas present numerous individual neoplastic
melanocytes present within the basal cell layer only, which is also referred to as an ‘atypical
lentiginous infiltrate’ [43].
Spindle cell and desmoplastic melanomas, a subgroup of dermal melanomas, is composed
predominantly of spindled melanocytes densely packed, or arranged loosely within abundant
pale stroma [43]. Occasionally, there is a prominent fibroblastic component associated with
the spindle shaped melanocytes, and collagen may become more abundant than the tumor
cells [43]. The vast majority are amelanotic, thus a Fontana–Masson stain usually is necessary
to detect the presence of melanin granules; cells are usually arranged in bundles or palisades,
mimicking tumors of neural origin [43].
Balloon cell melanoma (clear cell melanoma), possess large cells with a clear eosinophilic
cytoplasm [43]. The majority of balloon cell melanomas are amelanotic [43]. Some dust-like
melanin granules may be present in a few tumor cells, and Fontana–Masson staining may be
required for their demonstration [43,45]. These cells have a large vesicular nuclei with a
prominent nucleoli [7,43]. Mitotic activity is generally low [43,45] and these dermal masses
exhibit no junctional activity [45].
Signet-ring melanomas are composed of round to polygonal cells [45,52], with a pale eosino‐
philic cytoplasm and a darker periphery [52]. The nuclei are vesicular, crescent shaped and
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located at the periphery, giving the cells the appearance of signet-rings [52]. Nucleoli are
prominent and occasional multinucleated cells may be present [45].
7. Histochemical diagnosis
The histological diagnosis of melanoma can be a challenge for the pathologist, especially in
amelanotic tumours. On the other hand, in tumours heavily pigmented the observation of
cellular features could be very difficult, requiring the use of bleaching, a histochemical method
where melanin is extracted [7].
In cases where the diagnosis of a melanocytic tumor is not evident, histochemical methods
specific for the cells producing melanin, such as DOPA (dihydroxyphenylalanine) reaction can
be used [7,43].
8. Molecular diagnostic methods
A diagnosis of melanocytic tumors in dogs is not always easy to obtain only by conventional
histological methods. Melanoma is often similar to other tumours types and has a highly
variable histologic pattern which implies an accurate differential diagnosis. Furthermore, the
distinction between benign and malignant tumors is not always easy [7]. Thus, it is essential
the research of additional tools that can be used in melanocytic tumours diagnosis and to
achieve a more accurate prognosis [57].
8.1. Classical diagnostic markers
Several markers are used to evaluate the presence of proteins normally found in melanocytes
or in cells of neuroectoderm origin. The most common antibodies used are S-100 protein,
melanoma-associated antigen (Melan-A)/MART-1, HMB-45, MEL-1, vimentin, Neuron Specific
Enolase (NSE), microphthalmia transcription factor (MiTF), PNL2, tyrosinase, and tyrosinase-
related proteins 1 and 2 (TRP-1 and TRP-2). Tumor cells are usually positive for vimentin, S100,
neuron-specific enolase, and Melan-A, and negative for cytokeratin [7]. However, there is a
heterogeneneity of antigen expression. The majority of melanomas are S100 positive, but other
tumour types are also positive to this protein. NSE is also positive in smooth muscle and
neuroendocrine tumours. Melan-A and HMB-45 expression is not a constant in every canine
melanocytic tumours. Vimentin is expressed in other tumours as sarcomas [7,58-61]. HMB-45,
tyrosinase, and tyrosine hydroxylase showed 100% specific but low sensitivities. One study
refers that PNL2, TRP-1, and TRP-2 seems to be highly sensitive and specific for the diagnosis
of canine amelanotic tumours, but it was only performed in oral melanomas [62].
In the absence of an ideal marker that excludes definitively other tumour types, confirms a
diagnosis of canine melanoma and positively reacts with tumour cells in all melanomas, a
diagnostic panel must be performed, including different antibodies [58-61].
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8.2. Growth fraction
The proliferative activity has provided valuable information on cell growth kinetics and
consequently tumour behavior in melanocytic tumours [63]. There are some markers that
estimate tumor proliferation, by identifying steps associated with cell cycle [64].
MIB-1 is the monoclonal antibody which is reactive against Ki-67 nuclear antigen, a protein
present in all active phases of the cell cycle (G1, S, G2 and M) while being absent in resting
phase (G0) [65,66].
In canine melanocytic tumours, Ki-67 may be useful in distinction between benign and
malignant tumors: melanocytomas seem to have a significant lower growth fraction than
malignant melanomas [67]. Furthermore, KI-67 could be an important prognosis factor in
canine cutaneous melanocytic tumours [64,68].
8.3. DNA ploidy
Changes in DNA content may reflect chromosomal alterations and represent tumour genetic
instability [69-72]. Changes in the DNA ploidy constitute an early event in carcinogenesis
[73,74] and detection of aneuploid cell population of pre-neoplastic lesions can be considered
a factor risk of the emergence of malignant tumours [75]. Although usually benign tumors
were diploid [76] and aneuploidy were malignant [77], diploidy is not synonymous of a benign
behavior [78]. Moreover, not all malignant tumors are aneuploid [79,80].
There are few studies about the ploidy assessment in canine melanocytic tumors [81,82] and
its usefulness is still discussed. DNA index and ploidy balance seem to provide an additional
tool to evaluate melanocytic tumors, being useful in the distinction of benign and malignant
melanocytic tumours, mainly in amelanotic lesions [82]. Flow cytometry apparently has a
limited utility for predicting the biological behavior of pigmented canine melanomas. DNA
content and nuclear morphometric variables have little value in predicting survival time [83].
8.4. c-kit expression
The c-Kit protein (CD117), a transmembrane receptor that belongs to RTK III family, is a growth
factor for melanocyte migration and proliferation. A loss-of-function KIT mutation are usually
related with human melanocytic tumors [84,85].
In canine cutaneous melanocytic tumours, c-kit immunolabeling (both extension and intensity)
were generally higher in melanocytomas than in malignant melanomas. The lack of c-kit
expression in canine cutaneous malignant melanomas might be used as a criteria of tumor
aggressiveness, helping to achieve a proper diagnosis [86].
8.5. Matrix metalloproteinase 2 and 9 expression
MMPs are zinc- and calcium-dependent proteases that promove not only the disruption and
remodeling of structural barriers [87-89] but also a response to signaling molecules, acting as
ligand for cellular adhesion receptors [90-92].
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MMP-2 is widely distributed and constitutively expressed by most cells [93,94]. This protease
has major roles reducing cell adhesion, stimulating cell migration and differentiation, and
acting as an anti-inflammatory factor [95]. MMP-9 expression is normally induced, while
almost MMPs are constitutively secreted after their translation [93,96], and may act as anti- or
pro-inflammatory factors [95].
MMPs play a pivotal role in cancer development and progression [92,94,96-98] contributing
to tumour proliferation, invasion, intravasation into circulation, extravasation, migration to
metastatic sites and angiogenesis [90,94,99-101], deregulate the balance between growth and
antigrowth signals in the tumour microenvironment [97,102,103], orchestrate inflammation
[94,102,104], and evade apoptosis [89,91,102].
In canine cutaneous melanocytic tumours, MMP-2 and MMP-9 may be taken as a complement
to histology in tumour diagnosis, especially in borderline lesions. Both MMP-2 and MMP-9
were expressed in the majority of canine cutaneous melanocytic tumours. MMP-2 is most
commonly expressed in melanocytomas than in melanomas [105]. MMP-9 was overexpressed
in malignant melanomas, compared with its expression in melanocytomas [106].
Additionally, in canine malignant melanomas a switch may occur in the MMP expression
profile during tumour progression; meaning that the aggressiveness, evaluated by nucle‐
ar  grade,  seems to  be  associated with a  decrease  of  MMP-9 and an increase  of  MMP-2
expression [105].
8.6. Inflammatory cells associated to tumour
The  tumour  associated  inflammatory  infiltrate  may  be  modulate  and  determine  tumor
behavior  [107].  The  most  studied  cells  in  CCMT  are  macrophages  and  T-lymphocyte,
however, studies on the matter are scarce.
8.6.1. Tumour Associated Macrophages (TAMs)
Macrophages constitute the most abundant leukocytes in the tumor environment, recruited
by a number of chemoattractants that are produced by the tumor cells and tumor-associated
stroma [108,109]. TAMs play a critical role in tumour progression and invasion by inducing
neovascularization, suppressing immunocompetent cells and supporting cancer stem cells
[110-113].
One study published by our group found that canine cutaneous melanocytomas present a
lower number of TAMs than malignant melanomas. TAMs could constitute an important
marker  of  canine  melanocytic  aggressiveness,  being  implicated  in  the  progression  of
melanocytic precursor lesions to malignant melanoma [114].
8.6.2. T-Lymphocytic Infiltrate (TLI)
In spite of the fact that the role of the T-lymphocytic infiltrate in cancer tumourigenesis remains
controversial, several studies showed that the presence of TILs are related to tumoural
behavior in different tumour types [115,116].
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Preliminary studies of our group showed that there is a difference between TILs in benign and
malignant melanocytic neoplasms, whereas all melanocytomas presented little or even
absence of TILs and melanomas had a more intense TILs, (Figure 19), [117].
Figure 19. Abundant CD3+TILs in canine cutaneous melanoma (IHC, 100x), courtesy of Dr. Patricia Monteiro.
8.7. E-cadherin/β-catenin
Epithelial cadherin (E-cadherin) is a transmembranar glycoprotein which belongs to a family
of cell to cell adhesion molecules dependent of the present of calcium molecules to bind
cytoskeleton proteins through catenins. A decreased or altered expression of E-cadherin
molecules often represents an increased invasiveness of tumour cells and ultimately malig‐
nancy in animal and human epithelial tumours [118,119].
In canine melanocytic tumours, the benign lesions present a membranous labelling (Figure
20) and the malignant ones an erroneous labelling, with a cytoplasmatic predominant immu‐
nostaining. Additionally, a loss of E-cadherin expression is noted in melanoma [120]. A loss
of membrane E-cadherin/β-catenin complex is also detected in canine melanoma showing that
a disruption of E-cadherin/β-catenin complexes and a increase of β-catenin may be associated
with canine melanocytic tumours progression and aggressiveness [121].
8.8. Cox-1 and Cox-2 expression
Cyclooxygenase (COX), also known as the prostaglandin H-synthase, is an enzyme envolved
on prostanoids biosynthesis. Cox-1 and Cox-2 are the two cyclooxigenase isoforms identified
to date, similar in its structure but produced by different genes. The biological functions are
also different: Cox-1, constitutively expressed in many tissues, plays an important role in the
regulation of normal physiological, while Cox-2 is usually absent from normal cells but
induced by growth factors, inflammatory reactions, tumour promoters and oncogenes
[122-125].
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Cox-1  and  Cox-2  expression  was  recently  described  in  canine  melanocytic  tumours
[126-128].  Cox-1  is  expressed  in  almost  every  tumours,  both  benign  and  malignant
melanocytic  skin  lesions.  Regarding  Cox-2,  melanocytomas  did  not  present  a  positive
immunolabelling, but in melanomas Cox-2 expression was present in more than 50% of the
tumours [114,127]. The differences observed suggest that Cox-2 expression could be a useful
tool in canine melanoma diagnosis, particularly in borderline lesions.
COX-2 expression was also observed in tumours with epithelium ulceration, necrosis, high
mitotic index and nuclear grade and in less pigmented neoplasms, which could represent the
higher aggressiveness of Cox-2 positive melanocytic tumours. In canine malignant melano‐
mas, Cox-2 is associated with a higher cellular proliferation [114]. Besides the relation with
tumour behavior [127], Cox-2 over-expression relates with a poor overall survival [129].
8.9. Angiogenesis
Vascular system is essential in oxygen and nutrients supply, elimination of metabolism
products and promoting efficient access of leukocytes [130].
Angiogenesis is a complex process by which new blood vessels develop from pre-existing
vasculature [131-133]. It is a fundamental requirement for organs development. Angiogenesis
is also implicated in the pathogenesis of different pathological alterations, such as cancer and
inflammation [134-136].
The tumor-associated neovascularization, by establishing continuity with the systemic
circulation, allows tumor cells expressing their critical advantage in growth and facilitates
metastization [137-139].
8.9.1. Vascular endothelial growth factor
Angiogenesis is a delicate process, tightly regulated by the balance of pro- and anti-angiogenic
factors [140]. Among the angiogenic factors, VEGF is the more powerful and ubiquitous
Figure 20. Strong membranar E-cadherin expression (IHC, 200x), courtesy of Dr. Mariana Santos.
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vascular endothelial growth factor, capable of inducing proliferation, migration, specialization
and survival of endothelial cells [141,142]. Functions of VEGF family members related to
neoplastic pathogenesis are linked not only to its angiogenic capacity [143], but also with the
lymphangiogenesis [144,145], immunosuppression [146-148], stimulation and recruitment of
endothelial and hematopoietic precursors of the bone marrow [149,150] and anti-apoptotic
activity [150].
In canine melanomas, the only study published on VEGF expression is in oral melanomas.
High blood concentrations of VEGF were correlated to a shorter survival time in dogs receiving
definitive therapy and were associated with tumour stage [151].
This is a promising area, since VEGF may be a good indicator of preneoplastic change in
melanocytic lesions [137,152]. VEGF plays a role in human melanoma progression [153,154]
with a strong involvment in the switch from the radial to the vertical growth phase and the
metastatic phase. So, anti-angiogenic agents might even interfere with or block melanoma
progression [155].
Preliminary studies performed by Gomes J and Pires I (data unpublished) show that VEGF
may be useful as a discriminating factor between malignant melanoma and benign, since it is
more intensely expressed in melanomas (Figure 21) than in melanocytomas.
Figure 21. Canine cutaneous melanoma with a strong and diffuse VEGF expression (IHC, 200x), courtesy of Dr. Joana
Gomes.
8.9.2. Microvessel Density (MVD)
Tumor angiogenesis can be estimated through a quantification of microvessel density (MVD).
The most widely used method is the immunohistochemical methods, in which specific markers
for endothelial cells are employed, as von Willebrand factor (Figure 22), CD34 and CD31
[156-158].
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MVD seems to be important for diagnostic purposes in canine MT’s. MVD is significantly
higher in melanoma than in melanocytomas [159] and its expression has been associated with
a high mitotic index, necrosis and ulceration (study performed by Gomes J and Pires I, data
unpublished). However, its prognostic significance is still discussable [159,160].
Figure 22. Tumoural neovessels positive to von Willebrand factor (IHC, 400x), courtesy of Dr. Joana Gomes.
9. Conclusions
The incidence of melanoma is increasing annually both in man and in dog. Given that dogs
and humans share the same environment and similarities between human and canine
melanoma it is urgent to discuss common mechanisms in melanoma development in both
species.
Melanoma diagnosis in dogs can be challenging due to the variety of its histological appear‐
ances, especially when pathologists are facing amelanotic or metastatic lesions. Although the
definitive diagnosis of a melanoma is often difficult by the lack of specific markers that can
distinguish these lesions, immunohistochemistry plays a key role in the differential diagnosis
with other neoplasms.
Additionally, the distinction between benign and malignant melanocytic tumours is not
always easy, especially in borderline lesions, thus the importance of a strong knowledge of
new markers of malignancy for the establishment of a definitive diagnosis and a correct
therapy managment and prognosis establishment.
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